Holen Sie sich die Stockscreener-App
8.045
1.07%
0.085
Schlusskurs vom Vortag:
$7.96
Offen:
$7.98
24-Stunden-Volumen:
288.44K
Relative Volume:
0.17
Marktkapitalisierung:
$2.52B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-11.82
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
-2.60%
1M Leistung:
+1.64%
6M Leistung:
-8.68%
1J Leistung:
+8.28%
1-Tages-Spanne:
$7.93
$8.065
1-Wochen-Bereich:
$7.79
$8.305
52-Wochen-Spanne:
$6.50
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.045 | 2.59B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
153.44 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.74 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.55 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.35 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
What analysts say about Amneal Pharmaceuticals Inc. stockSignificant capital appreciation - Autocar Professional
What drives Amneal Pharmaceuticals Inc. stock priceLightning-fast growth - Autocar Professional
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - jammulinksnews.com
Is Amneal Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal reports 3% revenue growth in Q2, advances deleveraging - Investing.com India
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Quiver Quantitative
Amneal Pharmaceuticals Unveils Massive $2.55 Billion Debt Restructuring PlanWhat's Changing - Stock Titan
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times
Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.
Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN
Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire
Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports - insights.citeline.com
5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - FinancialContent
Amneal reports positive phase 3 results for XOLAIR biosimilar By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for AMRX - Nasdaq
Investing in Amneal Pharmaceuticals (NASDAQ:AMRX) three years ago would have delivered you a 157% gain - simplywall.st
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com
Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance
Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com
FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India
FDA approves Amneal's prednisolone acetate ophthalmic suspension - Eyes On Eyecare
Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener
Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan
Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):